RecruitingPhase 2NCT06794541

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)

Sponsor

Tetraphase Pharmaceuticals, Inc

Enrollment

35 participants

Start Date

May 22, 2025

Study Type

INTERVENTIONAL

Conditions

Complicated Intra-abdominal Infections (cIAI)

Summary

A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.

Eligibility

Min Age: 8 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IV Eravacycline 1.5mg/kg and a drug called IV Eravacycline 2mg/kg for people with complicated intra-abdominal infections (ciai). The study is currently recruiting participants at 5 locations. People eligible for this study include aged 8 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIV Eravacycline 2mg/kg

infused over a 60-minute period

DRUGIV Eravacycline 1.5mg/kg

infused over a 60-minute period

Locations(5)

UCLA Ronald Reagan University of California Los Angeles Medical Center

Los Angeles, California, United States

Children's Hospital of Orange County

Orange, California, United States

Ann and Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Children's Hospital of LSU Health Sciences Center Shreveport

Shreveport, Louisiana, United States

West Virginia University Medicine Children's Hospital

Morgantown, West Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06794541